Publicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (7)

2023

  1. Strategies to facilitate adolescent access to medicines: Improving regulatory guidance

    Clinical Trials, Vol. 20, Núm. 1, pp. 13-21

2021

  1. Immune checkpoint inhibitors in urothelial carcinoma: Recommendations for practical approaches to pd-l1 and other potential predictive biomarker testing

    Cancers, Vol. 13, Núm. 6, pp. 1-18

2020

  1. Combined MEK and PI3K/p110β inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features

    Cancer Research, Vol. 80, Núm. 4, pp. 843-856

2013

  1. Adaptation into Spanish of the Clinically Useful Depression Outcome Scale (CUDOS) for assessing major depressive disorder from the patient's perspective

    Actas Espanolas de Psiquiatria, Vol. 41, Núm. 5, pp. 287-300

2009

  1. Effectiveness and tolerability of oral ziprasidone in psychiatric inpatients with an acute exacerbation of schizophrenia or schizoaffective disorder: A multicenter, prospective, and naturalistic study

    Journal of Clinical Psychiatry, Vol. 70, Núm. 4, pp. 509-517

2008

  1. A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia

    International Clinical Psychopharmacology, Vol. 23, Núm. 3, pp. 138-149

2005

  1. A 6-month prospective observational study on the effects of quetiapine on sexual functioning

    Journal of Clinical Psychopharmacology, Vol. 25, Núm. 6, pp. 533-538